HMGB3在乳腺癌中的预后和功能：基于生物信息学分析

王文艺, 徐佳玮, 顾军

The prognosis and function of HMGB3 in breast cancer: Based on bioinformatics analysis

Wenyi Wang, Jiawei Xu, Jun Gu

表1 不同临床病理因素下乳腺癌中HMGB3表达与临床预后的相关性(Kaplan?Meier Plotter)

Table 1 Correlation of HMGB3 expression and clinical prognosis in breast cancer with different clinicopathological factors by Kaplan?Meier Plotter

		$R F S (n = 4939)$			$D M F S (n = 2767)$
		N	Hazard ratio	P	N	Hazard ratio	P
Total analysis		2032	1.54 (1.32~1.29）	2e~8	958	1.77 (1.35~2.32）	3.1e-05
ER	ER positive	902	1.49 (1.12~1.97)	0.006	248	2.27 (1.03~5.02)	0.037
ER	ER negative	470	0.91 (0.67~1.24)	0.55	270	1.21 (0.79~1.86)	0.37
PR	PR positive	511	1.41 (0.97~2.04)	0.072	144	2.18 (0.74~6.38)	0.15
PR	PR negative	436	1.29 (0.92~1.81)	0.14	266	1.38 (0.89~2.16)	0.15
HER2 positive		461	1.44 (1.06~1.95)	0.019	260	1.55 (0.98~2.45)	0.062
HER2 negative		1571	1.48 (1.24~1.76)	1.20E~05	698	1.41 (1.02~1.96)	0.04
Intrinsic subtype	basal	417	1.16 (0.86~1.58)	0.34	275	1.24 (0.78~1.99)	0.36
	luminal A	952	1.37 (1.07~1.75)	0.011	361	1.56 (0.93~2.6)	0.089
	luminal B	465	1.22 (0.9~1.64)	0.2	203	1.24 (0.7~2.22)	0.46
	HER2+	198	1.7 (1.09~2.66)	0.017	119	1.79 (0.97~3.3)	0.059
Lymph node positive		814	1.77 (1.39~2.27)	3.90E~06	261	2.4 (1.45~3.97)	0.00047
Lymph node negative		574	1.06 (0.73~1.54)	0.76	240	0.88 (0.44~1.76)	0.72
grade	1	113	0.97 (0.34~2.76)	0.95	44	NA
	2	243	1.23 (0.75~2.01)	0.42	91	1.93 (0.75~5)	0.17
	3	481	0.91 (0.68~1.22)	0.52	234	1.27 (0.76~2.12)	0.37
TP53	mutated	132	2.04 (1.11~3.75)	0.02	56	3.15 (0.98~10.14)	0.043
TP53	wild type	82	0.42 (0.17~1)	0.044	6	NA